aleniglipron vs VCT220

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Obesity

Shared mechanism: GLP-1 receptor · full Obesity pipeline

aleniglipron

Developed by Structure Therapeutics

Phase 3 in Obesitysmall molecule
Partial signal

NCT06703021 · Phase 2 · completed

The study was randomized, triple-blind, and placebo-controlled, with 85 participants. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.

Registered primary outcomes are safety measures; the weight-loss figures are the trial's prespecified efficacy readout, reported in the sponsor's topline press release and not yet peer reviewed. Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.

Next expected readout: September 2028 · NCT07654361 (registry estimate)

Reported efficacy

Treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs) (Baseline and week 44); Adverse events of special interest (Baseline and week 44); Number of Participants With Clinically Significant Change From Baseline in Laboratory Parameters, including hematology, plasma chemistry, coagulation, and urinalysis (Baseline and week 44); Number of Participants With Clinically Significant Change From Baseline in Electrocardiogram (ECG) Parameters: Common ECG-related variables will be assessed, including but not limited to : heart rate and QRS duration (Baseline and week 44); Number of Participants With Clinically Significant Change From Baseline in Vital Signs, including systolic and diastolic Blood Pressure, Heart Rate, Respiratory Rate, and temperature (Baseline and week 44): Placebo-adjusted mean weight loss 16.3% (39 lbs) at 180 mg and 16.0% (37 lbs) at 240 mg at 44 weeks (both p<0.0001) (not_applicable)

Result source: NCT06703021

VCT220

Developed by Ji Xing Pharmaceuticals (CORXEL) and partners

Phase 3 in Obesitysmall molecule
Partial signal

NCT06939296 · Phase 3 · completed

This was a randomized, double-blind Phase 3 trial with 840 participants. Its primary endpoint was met according to the sponsor's announcement of 2026-05-18. The result comes from the sponsor's announcement and the sources read give no power calculation, so the grade is moderate.

Next expected readout: March 2027 · NCT07652047 (registry estimate)

Reported efficacy

Percentage change from baseline in body weight (From baseline to week 34); The proportion of subjects with a body weight reduction ≥5% from baseline (From baseline to week 34): Primary endpoint met: 52-week weight loss about 12.2% and 12.4% vs 1.3% with placebo (2026-05-18). (met)

Result source: NCT06939296

Results for Obesity

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointaleniglipronVCT220
Body weight, % change—Trial running · NCT07654361—Not posted · NCT06939296
Weight loss of 5% or more—Trial running · NCT07654361—Not posted · NCT06939296
Weight loss of 10% or more—Trial running · NCT07654361—Not posted · NCT06939296
Waist circumference, change (cm)—Trial running · NCT07654361—Not posted · NCT06939296

Body weight, % change

aleniglipron
—Trial running · NCT07654361
VCT220
—Not posted · NCT06939296

Weight loss of 5% or more

aleniglipron
—Trial running · NCT07654361
VCT220
—Not posted · NCT06939296

Weight loss of 10% or more

aleniglipron
—Trial running · NCT07654361
VCT220
—Not posted · NCT06939296

Waist circumference, change (cm)

aleniglipron
—Trial running · NCT07654361
VCT220
—Not posted · NCT06939296
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

aleniglipron
Placebo-adjusted mean weight loss 16.3% (39 lbs) at 180 mg and 16.0% (37 lbs) at 240 mg at 44 weeks (both p<0.0001) NCT06703021 · Phase 2 · design grade: moderate · publication or press release
VCT220
Phase 2 trial, explicitly named as NCT07011797: primary endpoints met, up to 11.5% weight loss at 36 weeks with CX11 (oral GLP-1 receptor agonist), ongoing weight loss without plateau; gastrointestinal AEs the most common safety finding. NCT07011797 · Phase 2 · design grade: strong · publication or press release
Primary endpoint met: 52-week weight loss about 12.2% and 12.4% vs 1.3% with placebo (2026-05-18). NCT06939296 · Phase 3 · design grade: moderate · reviewed ClinicalTrials.gov result
Primary endpoint (mean % body weight change, baseline to week 16): -5.8% to -9.7% across VCT220 dose cohorts vs -1.6% placebo; 9.7% and 9.4% decrease at 160 mg fast/slow titration (p<=0.001) NCT06569355 · Phase 2 · design grade: strong · publication or press release

Type 2 Diabetes

Shared mechanism: GLP-1 receptor · full Type 2 Diabetes pipeline

aleniglipron

Developed by Structure Therapeutics

Phase 3 in Type 2 Diabetessmall molecule
Weak signal

NCT05762471 · Phase 1/2 · completed

The study randomized 142 participants to GSBR-1290 or placebo with participants, care providers, and investigators masked. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source. Its registered primary outcome on ClinicalTrials.gov is "Incidence, severity and relationship of AE/SAE, vital signs, laboratory measures and ECG to assess safety and tolerability of multiple oral doses of GSBR-1290 in HOV and T2DM". Its registered primary outcomes are safety, tolerability or dose-finding measures only, so the evidence grade is capped at weak.

Registered primary endpoint is safety/tolerability; the weight results are the phase 2a obesity cohort's efficacy readout from the sponsor's SEC-filed topline release, not yet peer reviewed.

Next expected readout: September 2028 · NCT07654374 (registry estimate)

Reported efficacy

Incidence, severity and relationship of AE/SAE, vital signs, laboratory measures and ECG to assess safety and tolerability of multiple oral doses of GSBR-1290 in HOV and T2DM (42 days): Placebo-adjusted mean weight decrease 6.2% (p<0.0001) at 12 weeks with GSBR-1290 120mg (n=37) vs placebo (n=27); 67% achieved >=6% and 33% >= 10% weight loss vs 0% for placebo (met)

Result source: NCT05762471

VCT220

Developed by Ji Xing Pharmaceuticals (CORXEL) and partners

Phase 2 in Type 2 Diabetessmall molecule
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: April 2027 · NCT07340320 (registry estimate)

No aligned efficacy figure on record for this race.

Results for Type 2 Diabetes

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointaleniglipronVCT220
HbA1c, change—Trial running · NCT07654374—Not reported
Body weight, change (kg)—Trial running · NCT07654374—Not reported
HbA1c below 7%—Trial running · NCT07654374—Not reported
Fasting plasma glucose, change—Trial running · NCT07654374—Not reported
3-point MACE (% with event)—Trial running · NCT07654374—Not reported

HbA1c, change

aleniglipron
—Trial running · NCT07654374
VCT220
—Not reported

Body weight, change (kg)

aleniglipron
—Trial running · NCT07654374
VCT220
—Not reported

HbA1c below 7%

aleniglipron
—Trial running · NCT07654374
VCT220
—Not reported

Fasting plasma glucose, change

aleniglipron
—Trial running · NCT07654374
VCT220
—Not reported

3-point MACE (% with event)

aleniglipron
—Trial running · NCT07654374
VCT220
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

VCT220: no structured comparison results are available for Type 2 Diabetes.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

aleniglipron
Placebo-adjusted mean weight decrease 6.2% (p<0.0001) at 12 weeks with GSBR-1290 120mg (n=37) vs placebo (n=27); 67% achieved >=6% and 33% >= 10% weight loss vs 0% for placebo NCT05762471 · Phase 1/2 · design grade: weak · publication or press release

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: aleniglipron's landscape · VCT220's landscape